# Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Canonical URL: https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-first-quarter-financial-results-and-clinical-program-progress
Ticker: VERU
Company: Veru Inc
Source: Veru Inc
Published: 2026-02-11 11:30 EST
Original Source URL: https://ir.verupharma.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-27 12:10 EST — [Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-of-enobosarm--ce89119d) — Source: Veru Inc
- 2026-07-07 12:30 EST — [Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day](https://biopharmsignal.com/news/VERU/veru-to-present-at-2026-obesity-weight-loss-drug-development-summit-and-pre-conf-f5d70201) — Source: Veru Inc
- 2026-05-13 10:30 EST — [Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress](https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress) — Source: Veru Inc
- 2026-05-06 12:30 EST — [Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th](https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-second-quarter-financial-results-on-may-13th) — Source: Veru
- 2026-03-09 12:30 EST — [Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-enrolls-first-patient-in-phase-2b-plateau-clinical-trial-of-enobosarm-and-semaglutide-combination-for-high-quality-weight-loss) — Source: Veru Inc
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)